Somatuline Autogel Injectable (Lanreotide)

Somatuline Autogel Injectable contains lanreotide, a somatostatin analog used for hormone regulation and symptom control. This prescription medication is administered subcutaneously to manage conditions like acromegaly and neuroendocrine tumors. Suitable for patients seeking targeted hormonal therapy with long-acting relief.

Lanreotide, the active ingredient in Somatuline Autogel Injectable, is primarily used to reduce symptoms associated with acromegaly by lowering growth hormone and insulin-like growth factor levels. It is also prescribed for neuroendocrine tumors to control hormone secretion and slow tumor progression. Patients often use this medication when surgery or other treatments are not suitable.

Somatuline Autogel Injectable works gradually to regulate hormone levels, which may help reduce symptoms such as headaches, joint pain, or flushing over time. Some users report improved comfort and fewer episodes of severe symptoms after consistent use. Individual responses vary based on condition and treatment duration.

Store Somatuline Autogel Injectable in a refrigerator until use, but avoid freezing. Keep the injection pen in its original packaging to protect from light. Always follow healthcare provider instructions for handling and disposal of used needles. Report any unusual reactions or injection site issues promptly.

Lanreotide may interact with medications that affect heart rhythm, such as antiarrhythmics, or drugs that alter blood sugar levels, including insulin. Caution is advised when combining with other hormonal therapies. Alcohol use may exacerbate certain side effects, so moderation is recommended. Always disclose all medications to your healthcare provider.